查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1499966

全球 ELISpot 和 FluoroSpot 检测市场评估：依产品、依应用、依最终用户、依地区、机会、预测，2017-2031 年

ELISpot and FluoroSpot Assays Market Assessment, By Product, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 210 Pages | 商品交期: 3-5个工作天内

价格

全球 ELISpot 和 FluoroSpot 检测市场规模预计将从 2023 年的 3.2123 亿美元成长到 2031 年的 6.1468 亿美元，在 2024-2031 年的预测期内复合年增长率为 8.45%。

酵素连结免疫斑点（ELISpot）检测因其出色的灵敏度而经常用于各种医学疾病的诊断。ELISpot 具有高度适应性，经常用于测量抗原特异性人类和小鼠 T 细胞。许多诊断采用多种类型的 ELISpot 检测，包括颗粒□ B ELISpot、TGF-β1 ELISpot、萤光 ELISpot 和 IFN-γ ELISpot。酵素连结免疫斑点 (ELISpot) 和萤光免疫斑点Fluorescent ImmunoSpot（FluoroSpot）检测特别适合检测活性细胞中的细胞激素等分泌蛋白。由于慢性病盛行率不断上升、人们对快速诊断需求的认识不断提高以及检测方法的使用不断扩大，预计 ELISpot 和 FluoroSpot 检测方法的市场将得到发展。

此外，不断增长的医疗保健支出支持了 ELISpot 和 FluoroSpot 检测在新兴国家的成长潜力。个人化医疗的普及是推动市场成长的关键因素。然而，阻碍市场扩张的因素包括价格上涨、缺乏高品质的检测试剂以及欠发达国家的 ELISpot 和 FluoroSpot 检测方法的可用性较低，这可以理解为市场的发展和成长机会。进行诊断测试时遇到的操作问题和材料使用不一致会促使市场竞争并为公司提供成长前景。

该报告考察了全球 ELISpot 和 FluoroSpot 检测市场，并提供了市场概述，包括依产品、应用、最终用户、地区和参与市场的公司概况划分的趋势。

目录

第1章 研究方法论

第2章 专案范围与定义

第3章 执行摘要

第4章 2017-2031 年全球 ELISpot 与 FluoroSpot 侦测市场展望

  • 市场规模及预测
  • 依产品
  • 依用途
  • 依最终用户
  • 依地区
  • 依公司划分的市占率 (%)，2023 年

第5章 全球 ELISpot 与 FluoroSpot 侦测市场展望（依地区划分，2017-2031 年）

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第6章 市场测绘，2023 年

第7章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第8章 市场动态

第9章 监理架构与创新

第10章 主要与企业状况

第11章 价格分析

第12章 案例研究

第13章 主要进入者展望

  • Becton, Dickinson and Company
  • Oxford Immunotec Ltd.
  • Bio-Techne Corporation
  • Mabtech AB
  • Merck KGaA
  • Cellular Technology Limited
  • U-CyTech BV
  • Abnova Corporation
  • Agilex Biolabs Pty Ltd
  • Biorbyt Ltd.

第14章 战略建议

第15章 查询及免责声明

Product Code: MX11504

Global ELISpot and FluoroSpot assays market is projected to witness a CAGR of 8.45% during the forecast period 2024-2031, growing from USD 321.23 million in 2023 to USD 614.68 million in 2031.

Due to its excellent sensitivity, the enzyme-linked immunospot (ELISpot) assay is frequently used to diagnose various medical disorders. They are very adaptable and are frequently used to measure human and mouse T cells that are specific to an antigen. Numerous diagnostic applications employ several types of ELISpot tests, such as Granzyme B ELISpot, TGF-Beta 1 ELISpot, Fluorescent ELISpot, and IFN-gamma ELISpot. Particularly well suited for secreted proteins, such as cytokines from active cells, are the ELISpot and Fluorescent ImmunoSpot (FluoroSpot) tests. The market for ELISpot and FluoroSpot assays is expected to develop due to the rising prevalence of chronic diseases, a rise in awareness of the need for prompt diagnosis, and the growing use of the assay.

Additionally, the rise in healthcare spending supports the potential for growth in emerging countries for the ELISpot and FluoroSpot assay. The popularity of personalized medicine is a crucial factor in promoting the market's growth. However, factors that could impede market expansion include rising prices, a lack of high-quality detection reagents, and the inaccessibility of the ELISpot and FluoroSpot assays for underdeveloped nations, which can be seen as development and growth opportunities in the market. Operation issues encountered when performing diagnostic tests and inconsistent material usage lead to market player competition, which presents businesses with growth prospects.

For instance, Virax Biolabs Group Limited announced the launch of an early access program for its proprietary SARS-Cov-2 ViraxImmune T-cell-based test in September 2023, intended solely for research purposes. The early access program offers unique access to advanced immunological evaluation discoveries for selected research organizations. Virax Biolabs Group Limited's T-cell-based test was designed to determine whether memory T-cells specific to the SARS-Cov-2 virus are activated. The test version is designated as Research Use Only (RUO). It is accomplished by mixing a peptide pool that covers specific viral protein sequences with an ELISpot assay. Peripheral blood mononuclear cells must be isolated from blood samples for the test and these cells must then be transferred onto an ELISpot plate that has already been coated by the company.

Growing Prevalence of Chronic Diseases to Fuel the Market Growth

The rising prevalence of chronic diseases is fueling the market growth of ELIspot and FLUROspot tests. The incidence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune diseases has increased dramatically worldwide, requiring advancements in diagnostic and therapeutic tools. ELIspot and FLUROspot assays have emerged as important technologies due to their sensitivity and specificity in detecting and quantifying immune responses. For instance, ELIspot and FLUROspot assays in oncology help assess the T-cell responses to cancer vaccines and immunotherapies, guiding treatment decisions and tracking therapeutic outcomes. The American Cancer Society estimated that there were 609,820 cancer deaths and 1,958,310 new cancer cases in the United States in 2023. Prostate cancer incidence rose by 3% a year on average. Similarly, in autoimmune diseases, these assays are instrumental in identifying autoreactive T-cells, aiding in diagnosing and managing conditions such as rheumatoid arthritis, tuberculosis, and multiple sclerosis. As per the World Health Organization's (WHO) 2023 report, 5.8 million men, 3.5 million women, and 1.3 million children worldwide were predicted to have contracted tuberculosis (TB) in 2022.

The rise in the prevalence of chronic diseases has spurred many research and development activities, leading to a demand for advanced immunoassay systems such as ELIspot and FLUROspot. Pharmaceutical and biotech companies use these assays in pre-clinical and clinical trials to assess the urgency of new therapeutic immune responses. Furthermore, the increasing awareness and adoption of drug personalization have emphasized the importance of accurate immune monitoring, which has led to the use of ELIspot and FLUROspot assays, increasing the emphasis. As healthcare systems worldwide continue to grapple with the burden of chronic diseases, the market for these assays is poised for robust growth, driven by the need for effective diagnostic and monitoring solutions.

Increasing Demand for Personalized Medicine

The ELIspot and FLUROspot assays market is developing substantially, mostly due to the rising need for personalized treatment. Accurate and trustworthy diagnostic instruments are essential for personalized medicine, accommodating medical care according to individual traits such as genetics and biomarkers. In this context, the use of ELIspot and FLUROspot assays, which are renowned for their excellent sensitivity and specificity in identifying and measuring cellular immune responses, is growing. With ELIspot assays, cytokine-secreting cells can be found at the single-cell level, providing a clear perspective on the status of the immune system. It is essential for personalized medicine, which frequently entails tracking patients' immune responses to customize therapies, especially in autoimmune disorders, infectious diseases, and malignancies.

The demand for accurate, high-throughput, and adaptable assays, such as ELIspot increases as treatments become more customized, which propels the market expansion. The same concept applies to FLUROspot assays, which integrate fluorescence detection with ELIspot principles to allow multiplexing or the simultaneous detection of several cytokines or other released chemicals from distinct cells. For instance, Agilex Biolabs Pty Ltd, an Australian bioanalytical laboratory, stated in April 2022 that it would expand its operations in the United States. Agilex Biolabs Pty Ltd has expanded to San Diego and opened a new facility in South Australia to investigate large-molecule treatments. The newly established laboratory is equipped with state-of-the-art bioanalytical equipment and procedures, including digital droplet quantitative RT-PCR analysis and the EliSPOT/FluoroSPOT multi-spot reader, which is used to detect highly sensitive molecules.

Personalized medicine benefits from multiplexing since it allows thorough immune profiling from small patient samples. The capacity to obtain a comprehensive understanding of immune responses unique to a patient speeds up the creation and refinement of customized treatments. Further driving its use, the developments in assay technologies, including automated platforms and better reagent formulations, increase the frequency of use of ELIspot and FLUROspot assays. As personalized medicine continues to grow, driven by advancements in genomics and biotechnology, the demand for sophisticated immune monitoring tools is expected to rise, sustaining the market growth for ELIspot and FLUROspot assays.

Increasing Dominance of Assay Kits

Assay kits are essential for drug development, environmental monitoring, and life science research. These applications encompass investigating disease pathways, identifying potential therapeutic candidates, and assessing the production processes of biopharmaceuticals. Due to factors such as the rising prevalence of chronic illnesses and the growing use of these goods for vaccine development in clinical studies, the assay kits segment continues to have a significant share in the market.

In the United States, there were an anticipated 2,060 bone cancer-related fatalities and 3,610 new cases in 2021, according to the American Society of Clinical Oncology's 2022 report. Since they are employed in the diagnosis of autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, and other conditions, it is expected that the prevalence of these diseases will propel the expansion of this market. Additionally, during the forecast period, innovation in ELISpot assay kits and the usefulness of assay kits in research activities are anticipated to propel the industry expansion. As a result, the test kit segment will grow over the projection period due to the widespread usage of assays for research studies and clinical trials.

For instance, the T-Cell Select reagent kit by Oxford Immunotec Ltd. was approved by the FDA in September 2022. The kit streamlines the process of the T-SPOT.TB test, an internationally regulated ELISPOT IGRA that identifies latent tuberculosis (TB) infection, for use in in-vitro diagnostic (IVD) procedures in accredited laboratories. It was launched to reduce the amount of time and money spent in labs while testing for tuberculosis. The CEO of PerkinElmer's Oxford Immunotec Ltd. division claimed that automation closes the gap between the ELISPOT and ELISA laboratory operations, enabling more laboratories to perform T-SPOT assays.

North America to Dominate Global ELISpot and FluoroSpot Assays Market Share

North America is anticipated to lead the ELISpot and FluoroSpot assay market for the forecast period due to an increase in the prevalence of infectious and chronic diseases. According to the American Cancer Society's Cancer Statistics 2022, leukaemia, lymphoma, and breast cancer will be among the 1,918,030 new cases of cancer expected to be diagnosed in the United States in 2022. Furthermore, one million Americans have chronic hepatitis B infections, which can result in chronic illnesses, including liver cancer, according to data released by the American Academy of Paediatrics in March 2022. It is anticipated to fuel the expansion of the ELISPOT assay, which is very helpful in diagnosing infectious diseases and raising the demand for vaccinations.

Additionally, the market is expanding due to technical developments in ELISpot and FluoroSpot test kits and analyzers. The major factor propelling the regional market's expansion is the substantial research that numerous research institutes do in collaboration with many pharmaceutical companies. The adoption and expansion of the market in the area are anticipated to be fueled by the rapidly developing infrastructure, significant government investments in research and development, and the rising demand for innovative medicinal medications in nations such as the United States and Canada.

Future Market Scenario (2024 - 2031F)

Factors contributing to the anticipated growth of the ELISpot and FluoroSpot assays market are the increasing prevalence of chronic disorders, the increasing geriatric population, and the increasing demand for personalized medicines. Also, the rising population and sedentary lifestyles are factors that will propel the market growth in the future. As technology advances, we can expect the introduction of advanced technologies. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, ProImmune Ltd. introduced the B-cell ELISpot assay service in April 2022. A technique for assessing the immune response of B cells, which are essential for the body's defense against infections, immunological modulators, vaccinations, and medicinal medications, is the B cell ELISpot assay. Researchers can measure the number of B cells that produce a specific antibody in response to a certain stimulation to evaluate the effectiveness of vaccines or the potency of medicinal medications.

Key Players Landscape and Outlook

Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives for launching new assays, facilitating research and development, and increasing their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve a higher market share.

In June 2022, Becton, Dickinson and Company and CERTEST BIOTEC, S.L worked together to develop a molecular diagnostic test for the virus that causes monkeypox, a rare illness closely linked to the smallpox virus. The partnership seeks to enhance the identification and treatment of cases of monkeypox. The assay will use the Becton, Dickinson, and Company MAXTM open system reagent suite as part of the cooperation to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAXTM System. Users of the BD MAXTM will have access to the assay, which could contribute to our understanding of the disease's global spread.

Laboratory Corporation of America and Xcell Biosciences Inc. collaborated in April 2022 to strengthen and enhance vital laboratory operations, emphasizing cell and gene therapies. Laboratory Corporation of America can enhance its comprehensive suite of CGT capabilities through this arrangement, further supporting several other biotech and pharmaceutical companies.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global ELISpot and FluoroSpot Assays Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Assay Kits
      • 4.2.1.1. Assay Kits by Technique
        • 4.2.1.1.1. ELISpot Assay Kits
        • 4.2.1.1.2. FluoroSpot Assay Kits
      • 4.2.1.2. Assay Kits by Utility
        • 4.2.1.2.1. Diagnostic Kits
        • 4.2.1.2.2. Research Kits
      • 4.2.1.3. Assay Kits by Analyte
        • 4.2.1.3.1. T-cell Based Kits
        • 4.2.1.3.2. B-cell Based Kits
    • 4.2.2. Analyzers
    • 4.2.3. Ancillary Products
  • 4.3. By Application
    • 4.3.1. Diagnostic Applications
      • 4.3.1.1. Infectious Diseases
      • 4.3.1.2. Transplants
    • 4.3.2. Research Applications
      • 4.3.2.1. Vaccine Development
      • 4.3.2.2. Clinical Trials
      • 4.3.2.3. Cancer Research
  • 4.4. By End-user
    • 4.4.1. Hospital and Clinical Laboratories
    • 4.4.2. Research Institutes
    • 4.4.3. Contract Manufacturing Companies
    • 4.4.4. Pharmaceutical and Biopharmaceutical Companies
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global ELISpot and FluoroSpot Assays Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Assay Kits
        • 5.1.2.1.1. Assay Kits by Technique
          • 5.1.2.1.1.1. ELISpot Assay Kits
          • 5.1.2.1.1.2. FluoroSpot Assay Kits
        • 5.1.2.1.2. Assay Kits by Utility
          • 5.1.2.1.2.1. Diagnostic Kits
          • 5.1.2.1.2.2. Research Kits
        • 5.1.2.1.3. Assay Kits by Analyte
          • 5.1.2.1.3.1. T-cell Based Kits
          • 5.1.2.1.3.2. B-cell Based Kits
      • 5.1.2.2. Analyzers
      • 5.1.2.3. Ancillary Products
    • 5.1.3. By Application
      • 5.1.3.1. Diagnostic Applications
        • 5.1.3.1.1. Infectious Diseases
        • 5.1.3.1.2. Transplants
      • 5.1.3.2. Research Applications
        • 5.1.3.2.1. Vaccine Development
        • 5.1.3.2.2. Clinical Trials
        • 5.1.3.2.3. Cancer Research
    • 5.1.4. By End-user
      • 5.1.4.1. Hospital and Clinical Laboratories
      • 5.1.4.2. Research Institutes
      • 5.1.4.3. Contract Manufacturing Companies
      • 5.1.4.4. Pharmaceutical and Biopharmaceutical Companies
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
        • 5.1.5.1.1. By Value
        • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Product
        • 5.1.5.2.1. Assay Kits
          • 5.1.5.2.1.1. Assay Kits by Technique
          • 5.1.5.2.1.1.1. ELISpot Assay Kits
          • 5.1.5.2.1.1.2. FluoroSpot Assay Kits
          • 5.1.5.2.1.2. Assay Kits by Utility
          • 5.1.5.2.1.2.1. Diagnostic Kits
          • 5.1.5.2.1.2.2. Research Kits
          • 5.1.5.2.1.3. Assay Kits by Analyte
          • 5.1.5.2.1.3.1. T-cell Based Kits
          • 5.1.5.2.1.3.2. B-cell Based Kits
        • 5.1.5.2.2. Analyzers
        • 5.1.5.2.3. Ancillary Products
      • 5.1.5.3. By Application
        • 5.1.5.3.1. Diagnostic Applications
          • 5.1.5.3.1.1. Infectious Diseases
          • 5.1.5.3.1.2. Transplants
        • 5.1.5.3.2. Research Applications
          • 5.1.5.3.2.1. Vaccine Development
          • 5.1.5.3.2.2. Clinical Trials
          • 5.1.5.3.2.3. Cancer Research
      • 5.1.5.4. By End-user
        • 5.1.5.4.1. Hospital and Clinical Laboratories
        • 5.1.5.4.2. Research Institutes
        • 5.1.5.4.3. Contract Manufacturing Companies
        • 5.1.5.4.4. Pharmaceutical and Biopharmaceutical Companies
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Application
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Becton, Dickinson and Company
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Oxford Immunotec Ltd.
  • 13.3. Bio-Techne Corporation
  • 13.4. Mabtech AB
  • 13.5. Merck KGaA
  • 13.6. Cellular Technology Limited
  • 13.7. U-CyTech BV
  • 13.8. Abnova Corporation
  • 13.9. Agilex Biolabs Pty Ltd
  • 13.10. Biorbyt Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 2. Global ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 4. Global ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 5. Global ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global ELISpot and FluoroSpot Assays Market Share (%), By Region, 2017-2031F
  • Figure 7. North America ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 8. North America ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 10. North America ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 11. North America ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America ELISpot and FluoroSpot Assays Market Share (%), By Country, 2017-2031F
  • Figure 13. United States ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 14. United States ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 16. United States ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 17. United States ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 19. Canada ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 21. Canada ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 22. Canada ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 24. Mexico ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 26. Mexico ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 27. Mexico ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 29. Europe ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 31. Europe ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 32. Europe ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe ELISpot and FluoroSpot Assays Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 35. Germany ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 37. Germany ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 38. Germany ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 39. France ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 40. France ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 42. France ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 43. France ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 45. Italy ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 47. Italy ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 48. Italy ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 50. United Kingdom ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 52. United Kingdom ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 53. United Kingdom ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 55. Russia ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 57. Russia ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 58. Russia ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 60. Netherlands ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 62. Netherlands ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 63. Netherlands ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 65. Spain ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 67. Spain ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 68. Spain ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 70. Turkey ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 72. Turkey ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 73. Turkey ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 75. Poland ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 77. Poland ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 78. Poland ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 80. South America ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 82. South America ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 83. South America ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America ELISpot and FluoroSpot Assays Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 86. Brazil ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 88. Brazil ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 89. Brazil ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 91. Argentina ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 93. Argentina ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 94. Argentina ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 96. Asia-Pacific ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 98. Asia-Pacific ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 99. Asia-Pacific ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific ELISpot and FluoroSpot Assays Market Share (%), By Country, 2017-2031F
  • Figure 101. India ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 102. India ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 104. India ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 105. India ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 106. China ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 107. China ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 109. China ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 110. China ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 112. Japan ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 114. Japan ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 115. Japan ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 117. Australia ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 119. Australia ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 120. Australia ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 122. Vietnam ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 124. Vietnam ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 125. Vietnam ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 127. South Korea ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 129. South Korea ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 130. South Korea ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 132. Indonesia ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 134. Indonesia ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 135. Indonesia ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 137. Philippines ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 139. Philippines ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 140. Philippines ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 142. Middle East & Africa ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 144. Middle East & Africa ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 145. Middle East & Africa ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa ELISpot and FluoroSpot Assays Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 148. Saudi Arabia ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 150. Saudi Arabia ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 151. Saudi Arabia ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 153. UAE ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 155. UAE ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 156. UAE ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa ELISpot and FluoroSpot Assays Market, By Value, in USD Million, 2017-2031F
  • Figure 158. South Africa ELISpot and FluoroSpot Assays Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa ELISpot and FluoroSpot Assays Market Share (%), By Product, 2017-2031F
  • Figure 160. South Africa ELISpot and FluoroSpot Assays Market Share (%), By Application, 2017-2031F
  • Figure 161. South Africa ELISpot and FluoroSpot Assays Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Product Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 163. By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023